| HOME >> BIOLOGY >> TECHNOLOGY |
Long-term portion of restructuring costs 434 868
Long-term deferred revenue 6,071 1,783
Other long-term liabilities 297 337
Total liabilities 63,260 46,937
Stockholders' equity
Common stock 132 131
Additional paid-in capital 283,082 277,892
Accumulated other comprehensive loss (6) (124)
Accumulated deficit (282,501) (263,991)
Total stockholders' equity 707 13,908
Total liabilities and
stockholders' equity $63,967 $60,845
(1) The balance sheet data at December 31, 2006 is derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission.
Contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624 4576 Tel: 415 677 2700
amerriweather@ jeremiah.hall@
monogrambio.com fkhealth.com
| SOURCE Monogram Biosciences, Inc. Copyright©2007 PR Newswire. All rights reserved |